[Cardioneurological aspects of antiplatelet therapy in secondary prevention of cardiovascular diseases].
The paper reflects contemporary views of the role of antiplatelet therapy in secondary prevention of cardiovascular diseases in patients with coronary heart disease and ischemic stroke. On the basis of evidence based medicine analytical characteristics of all antiplatelet drugs subjected to clinical trials in the world are presented. Advantages and imperfectness of each agent both as monotherapy and used in combinations are demonstrated. Main principles of selection of antiplatelet drugs in patients after ischemic stroke, myocardial infarction, or in stable manifestations of coronary atherosclerosis are also given.